Neuraminidase treated cells and their role in cancer immunotherapy.
D000230:Adenocarcinoma / Q000517:prevention & control; D000818:Animals; D000951:Antigens, Neoplasm / Q000008:administration & dosage; D001500:BCG Vaccine / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D005354:Fibrosarcoma / Q000139:chemically induced / Q000276:immunology / Q000378:metabolism / Q000517:prevention & control*; D007167:Immunotherapy; D008325:Mammary Neoplasms, Experimental / Q000517:prevention & control; D008748:Methylcholanthrene / Q000009:adverse effects; D051379:Mice; D008815:Mice, Inbred Strains; D008937:Mitomycins / Q000008:administration & dosage / Q000494:pharmacology; D009362:Neoplasm Metastasis; D009365:Neoplasm Regression, Spontaneous; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000139:chemically induced; D009439:Neuraminidase / Q000494:pharmacology; D014734:Vibrio cholerae / Q000201:enzymology
D000951:Antigens, Neoplasm; D001500:BCG Vaccine; D008937:Mitomycins; D008748:Methylcholanthrene; D009439:Neuraminidase